The Food and Drug Administration’s approval in 2023 of lecanemab—a novel Alzheimer’s therapy shown in clinical trials to modestly slow disease progression—was met with enthusiasm by many in the field as it represented the first medication of its kind able to influence the disease. But side effects—brain swelling and bleeding—emerged during clinical trials that have left some patients and physicians hesitant about the treatment.
This article was originally published on MedicalXpress.com
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
Fostering a rewarding and fulfilling relationship is no easy task. You and your partner are only human, and, as the saying goes, you are going to make mistakes. However, learning the common relationship mistakes and […]
© 2025 SimplyWell.ca